Endokrinologie 2007

Was ist neu?

• Polyzystisches Ovarsyndrom: Neue Erkenntnisse zu kardiometabolischen Folgen

• Androgendefizit: Diagnostische Algorithmen

• Metabolische Folgen des Androgendefizits: Bedeutung der frühzeitigen Erkennung und Behandlung

Literatur

• 1 Asuncion M, Calvo R M, San Millan J L. et al . A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.  J Clin Endocrinol Metab. 2000;  85 2434-2438
• 2 Basaria S, Muller D C. et al . Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therpy.  Cancer. 2006;  106 581-586
• 3 Basin S, Enzlin P, Coriello A, Basson R. Sexual dysfunction in men and women with endocrine disorders.  Lancet. 2007;  369 597-611
• 4 Bhasin S, Cunningham G R, Hayes F J. et al . Testosteron therapy in adult men with androgen deficiency syndromes: an Endocrin Society Clinical Practice Guideline.  J Clin Endocrinol Metabol. 2006;  91 1995-2000
• 5 Brettenthaler N. et al . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 3835-3840
• 6 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.  Endocr Rev. 1997;  18 774-800
• 7 Hahn S, Haselhorst U, Quadbeck B. et al. . Decreased soluble receptor levels in women with polycystic overy syndrome.  Eur J Endocrinol. 2006;  154 287-294
• 8 Heutling D, Schulz H. et al . Asymmetric dimethylarginine and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.  J Clin Endocrinol Metab;. , in Revision.
• 9 Jayagopal V, Kilpatrick E S, Holding S. et al . Orlistat is as beneficial as Metformin in the Treatment of Poycystic Ovarian Syndrome.  J Clin Endocrinol Metab. 2005;  90 729-733
• 10 Kapoor D, Aldred H, Clark S. et al . Clinical and biochemical assessment of hypogonadism in men with type 2 dianetes: correlations with bioavailable testosterone and visceral adiposity.  Diab Care. 2007;  30 911-907
• 11 Kapoor D, Goodwin E, Channer K S, Jones T H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.  Eur J Endocrinol. 2006;  154 899-906
• 12 Kauffmann I M, Vermeulen A K. The decline of androgen levels in elderly men and ist clinical and therapeutic implications.  Endocr Rev. 2005;  26 833-876
• 13 Kupelian V, Page S T, Araujo A B. et al . Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with the development of the metabolic syndrome in non-obese men.  J Clin Endocrinol Metab. 2006;  91 843-850
• 14 Laaksonen D E. et al . Testosteron and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle aged men.  Diab Care. 2004;  27 1036-1041
• 15 Legro R S. et al . Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenämia rather than menstrual irregularity.  J Clin Endocrinol Metab. 2002;  87 2128-2133
• 16 Legro R S, Zaino R J, Memers L M. et al . The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.  Am J Obstet Gynecol. 2007;  196 402.e1-10
• 17 Lewandowski K C. et al . Adiponectin and Resistin Serum Levels In Women With Polycystic Ovary Syndrome During Oral Glucose Tolerance Test (OGTT): A Significant Reciprocal Correlation Between Adiponectin And Resistin Independent Of Insulin Resistance Indices.  Mol Genet Metab. 2005;  85 61-69
• 18 Lord J M, Flight I CH, Norman R J. Metformin in polycystic ovary syndrome.  BMJ. 2003;  327 951-953
• 19 Luque-Ramirez M, Alvarez-Blesco F. et al . Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  , ; epub ahead of print
• 20 Muller M, Grobbee D E, den Tonkelar I. et al . Endogenous sex hormones and metabolic syndrome in aging men.  J Clin Endocrinol Metab. 2005;  90 2618-2623
• 21 Orio F, Matarese G, Di Biase S. et al . Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 5887-5892
• 22 Orio F, Palomba S, Spinelli L. et al . The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.  J Clin Endocrinol Metab. 2004;  89 3696-3701
• 23 Palomba S, Falbo A, Russo T. et al . Insulin sensitivity after medformin suspension in normal-weight woman with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  , ; epub ahead of print
• 24 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome.  Fertil Steril. 2004;  81 19-25
• 25 Seow K M. et al . Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance.  Human Reproduction. 2004;  19 48-53
• 26 Shores M M, Matsumoto A M, Sloan K L, Kirlahan D R. Low serum testosteron and mole veterans.  Arch Int Med. 2006;  166 1660-1665
• 27 Talbott E O. et al . Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 5454-5461
• 28 Weyer C. et al . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
• 29 Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men.  J Clin Endocrinol Metab. 2006;  91 4335-4343